Phathom Pharmaceuticals, Inc. PHAT

Rank #1985 · Nasdaq · $0.5B market cap

⚠ Going-concern flag — the auditor (Ernst & Young LLP) raised substantial doubt about this company's ability to continue operating in the latest filing. Read the actual filing before drawing conclusions.

Score

37.1

P/E

-1.4

P/B

-6.29

ROE

459.5%

Op. Margin

-502.2%

Debt Ratio

-868%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆

Poor

P/E -1.4x, P/B -6.29x. Ranks in the top 98% of the universe.

Profitability ★★★☆☆

Average

ROE 459.5%. Ranks in the top 48% of the universe.

Safety ★★★★★

Excellent

Debt ratio -868%. Ranks in the top 2% of the universe. Under 100% is generally considered a safe level.

Growth ★★★★★

Excellent

Revenue growth of 8001.5% year over year. Ranks in the top 0% of the universe.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FY	Revenue	Op. Income	Net Income	Equity	Op. Margin%	Debt%
2019	–	$-0.0B	$-0.0B	$0.0B	–	–
2020	–	$-0.1B	$-0.3B	$-0.0B	–	-2272
2021	–	$-0.1B	$-0.1B	$0.2B	–	44
2022	–	$-0.1B	$-0.1B	$0.2B	–	60
2023	$0.0B	$-0.2B	$-0.2B	$0.1B	–	332
2024	$0.0B	$-0.2B	$-0.2B	$-0.1B	-24532.6	-650
2025	$0.1B	$-0.3B	$-0.3B	$-0.1B	-502.2	-868

← See the full screener